Eyebiotech targets Wnt pathway with first retinal program

A year after launching with $65 million to build out a pipeline of next-generation ophthalmic therapies, Eyebiotech is disclosing details of its lead program ahead of entering the clinic this year.

Eyebiotech Ltd. launched in February 2022 with a $65 million series A round from a syndicate of blue-chip VCs that were banking on the team of serial entrepreneurs in ophthalmology to recreate their previous successes, which include the first approval of an anti-VEGF therapy to treat wet age-related macular degeneration (AMD) while at Eyetech Pharmaceuticals Inc. ...